Yes. Must connect dots to sort news since BIAD currently not reporting but keep eye on BIAD partner thru MML, Zenosense. Ticker "ZENO"
MIDS progressing nicely. More news of progress "in coming weeks". Stay tuned. At $400K market cap BIAD biotech undervalued by minimum factor 10x.
"Our joint venture partner in MML has received a United States Patent and Trademark Office grant for the issuance of the central MIDS patent under number 9,678,064 in the U.S., namely: "Immunoassay Apparatus Incorporating Microfluidic Channel".
This is as a result of a patent application originally filed in 2011 by our MML joint venture partner. It is one of a number of applications made in commercially crucial regions for patent protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other applications have also successfully progressed into the national phase in the EU and India. This issuance in the U.S. indicates that these latter territories are also likely to progress to grant and, if so, will establish intellectual property protection in these key commercial regions. The MIDS patents are under license for the exclusive use by MML and will be transferred directly to MML in the event of the conclusion of a relevant commercial deal with a third party.
Carlos Gil, CEO of Zenosense Inc., commented: "This latest grant of the MIDS patent in the U.S. further validates our confidence in the ability of the MML team to deliver this exciting technology. I also expect to be able to provide a further update on development activities in the coming weeks."
News 
Market Data 
Discover 
